Wave Life Sciences (WVE) Net Equity Issued and Repurchased (2015 - 2025)

Wave Life Sciences (WVE) has 9 years of Net Equity Issued and Repurchased data on file, last reported at $330.9 million in Q4 2025.

• Quarterly Net Equity Issued and Repurchased rose 2294.44% year-over-year to $330.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $518.6 million (up 157.06% YoY) and the FY2025 annual result came in at $330.9 million, up 64.01% from the prior year.
• Net Equity Issued and Repurchased improved to $330.9 million in Q4 2025, from $13.8 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $330.9 million in Q4 2025 to a low of -$229000.0 in Q3 2022.
• A 5-year average of $56.3 million and a median of $13.8 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased sank 102.85% — and 2023, when it soared 623926.67%.
• Tracing WVE's Net Equity Issued and Repurchased over 5 years: stood at $33.8 million in 2021, then plunged by 100.04% to -$15000.0 in 2022, then soared by 623926.67% to $93.6 million in 2023, then sank by 85.23% to $13.8 million in 2024, then soared by 2294.44% to $330.9 million in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $330.9 million (Q4 2025), $13.8 million (Q4 2024), and $173.9 million (Q3 2024), per Business Quant data.